Biogen Inc.
Neuroscience company developing diranersen (BIIB080 / IONIS-MAPTRx), an antisense oligonucleotide designed to target MAPT mRNA and reduce tau production, evaluated in the Phase 2 CELIA study in early Alzheimer's disease.
Longevity thesis
If lowering tau production alters the course of an age-associated neurodegenerative disease, MAPT-directed antisense becomes a testable mechanism-level intervention rather than a symptomatic one.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| Diranersen | Phase 2 | Alzheimer's disease |
Recent developments
- 14 May 2026Company reported Phase 2 CELIA results: the primary endpoint assessing dose response for change from baseline on CDR-SB at Week 76 was NOT met; the company reported reductions in tau pathology, prespecified cognitive analyses it describes as showing slowing of clinical decline, and plans to advance diranersen to registrational development.
Scientific evidence
Company-reported only. LONGEFI holds no independent Evidence Record for diranersen. CELIA did not meet its primary endpoint; nothing here adjudicates efficacy, validates the tau hypothesis, or implies approval.
LONGEFI analysis
LONGEFI records the diranersen programme identity, target, technology, indication, stage and currentness only. Trial interpretation is deliberately out of scope for Company Knowledge.
Analysis is research commentary. It is not investment advice or a recommendation.